Literature DB >> 17022045

Megakaryocytic blast crisis as first presentation of chronic myeloid leukemia.

L Campiotti1, A M Grandi, M G Biotti, C Ultori, F Solbiati, R Codari, A Venco.   

Abstract

We describe an extremely rare case of megakaryocytic blast crisis as first presentation of chronic myeloid leukemia. The patient had a very high platelet count and developed an ischemic stroke with seizures. She was treated with hydroxyurea, platelet apheresis, ARA-C, and idarubicin in order to obtain a prompt reduction of thrombocytosis and then with imatinib 600 mg/die PO. The therapy induced a complete hematological remission with a resolution of neurological signs within 4 weeks. Copyright (c) 2006 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17022045     DOI: 10.1002/ajh.20797

Source DB:  PubMed          Journal:  Am J Hematol        ISSN: 0361-8609            Impact factor:   10.047


  5 in total

Review 1.  [Stroke in cancer patients. A paraneoplastic neurological syndrome?].

Authors:  W Grisold; M Födinger; S Oberndorfer
Journal:  Nervenarzt       Date:  2010-04       Impact factor: 1.214

2.  De novo acute megakaryoblastic leukemia with p210 BCR/ABL and t(1;16) translocation but not t(9;22) Ph chromosome.

Authors:  Xiao Min; Zhang Na; Liu Yanan; Li Chunrui
Journal:  J Hematol Oncol       Date:  2011-11-10       Impact factor: 17.388

3.  Chronic myeloid leukemia blast crisis presented with AML of t(9;22) and t(3;14) mimicking acute lymphocytic leukemia.

Authors:  Keyu Liu; Jintian Hu; Xueqin Wang; Li Li
Journal:  J Clin Lab Anal       Date:  2019-06-19       Impact factor: 2.352

4.  Comparative Gene Expression Analysis Reveals Similarities and Differences of Chronic Myeloid Leukemia Phases.

Authors:  Annemarie Schwarz; Ingo Roeder; Michael Seifert
Journal:  Cancers (Basel)       Date:  2022-01-05       Impact factor: 6.639

5.  In vitro effects of imatinib on CD34+ cells of patients with chronic myeloid leukemia in the megakaryocytic crisis phase.

Authors:  Fankai Meng; Wen Zeng; Lifang Huang; Shuang Qin; Ningning Miao; Hanying Sun; Chunrui Li
Journal:  Oncol Lett       Date:  2014-01-02       Impact factor: 2.967

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.